Hematology/Oncology

Top Story

Adjunctive systemic therapy: A reasonable option for patients with muscle-invasive bladder cancer

Adjunctive systemic therapy: A reasonable option for patients with muscle-invasive bladder cancer
HemOnc Today, July 25, 2016
Donald L. Trump, MD, FACP

It is with considerable trepidation that I undertake the assignment to comment on — nay, adjudicate — the “point” and “counter” positions staked out by two of my favorite people: Ian F. Tannock, MD, PhD, and Derek Raghavan, MD, PhD.

One of the advantages of long experience is the opportunity to nurture relationships — and disagreements — among those who are similarly experienced in my chosen discipline: genitourinary medical oncology.

Cover Story

Immunotherapy, tumor profiling fill ‘gigantic knowledge gap’ in bladder cancer

HemOnc Today, July 25, 2016
The standard of care for patients with bladder cancer has remained largely unchanged for nearly 3 decades. The NCI estimates that 76,960 Americans will be diagnosed with…
In the Journals

Obesity may increase risk for pediatric VTE

HemOnc Today, July 25, 2016
Obesity may be a significant risk factor for venous thromboembolism among children, according to results of a single-institution study. Multiple risk factors for…
Commentary

How the making of it matters

HemOnc Today, July 25, 2016
Christine Cserti-Gazdewich, MD, FRCPC
We started with the idea that red cells are resilient. They live for 120 days, traversing capillaries and splenic meshes narrower than their unsprung diameters, while…
Editorial

Word salad: What’s for dessert?

HemOnc Today, July 25, 2016
Derek Raghavan, MD, PhD
I enjoyed this year’s ASCO Annual Meeting. The program committee has finally taken very seriously the entreaties from Lowell E. Schnipper, MD, and the gang…
More News Headlines »
CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Video
Meeting News Coverage

VIDEO: CPX-351 demonstrates survival advantage in patients with secondary AML

July 21, 2016
More »
Featured
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan
morganatic-roan